Nektar Therapeutics (NKTR)
Nektar Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
7.0M
Short interest
settlement 2026-10-15
3.5
Days to cover
-0.2 days vs prior
50.0%
Short share of volume
2026-11-02
403
Fails to deliver
settlement 2026-10-14
Thu 5 Nov
Next earnings
estimated date
-$43K
Insider flow, 90 days
0 buys, 2 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in NKTR is 6,997,725 shares, up 1,262,092 shares over the last month. Over the last 48 readings it ranged from 595,786 shares (13 June 2025) to 11,304,921 shares (30 May 2025). At the reported average volume of 2.0M shares a day that is 3.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/nktr" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 6,997,725 | +0.4% | 1,989,553 | 3.52 |
| 2026-09-30 | 6,968,325 | +21.5% | 1,851,733 | 3.76 |
| 2026-09-15 | 5,735,633 | -5.5% | 757,194 | 7.57 |
| 2026-08-31 | 6,068,214 | -1.6% | 530,094 | 11.45 |
| 2026-08-14 | 6,168,872 | -2.1% | 591,702 | 10.43 |
| 2026-07-31 | 6,302,638 | -7.6% | 731,333 | 8.62 |
| 2026-07-15 | 6,819,180 | -1.1% | 978,241 | 6.97 |
| 2026-06-30 | 6,896,119 | +39.5% | 1,541,678 | 4.47 |
| 2026-06-15 | 4,944,195 | +7.2% | 1,002,078 | 4.93 |
| 2026-05-29 | 4,612,979 | +5.6% | 867,971 | 5.31 |
| 2026-05-15 | 4,368,267 | +6.5% | 838,245 | 5.21 |
| 2026-04-30 | 4,102,558 | +13.0% | 1,658,418 | 2.47 |
| 2026-04-15 | 3,631,077 | -0.9% | 628,205 | 5.78 |
| 2026-03-31 | 3,663,438 | -0.2% | 844,767 | 4.34 |
| 2026-03-13 | 3,669,934 | +9.8% | 968,788 | 3.79 |
| 2026-02-27 | 3,342,020 | -4.3% | 975,620 | 3.43 |
| 2026-02-13 | 3,490,770 | +6.2% | 2,235,175 | 1.56 |
| 2026-01-30 | 3,287,467 | +0.7% | 710,180 | 4.63 |
| 2026-01-15 | 3,263,647 | +11.2% | 700,100 | 4.66 |
| 2025-12-31 | 2,935,715 | +52.3% | 1,283,717 | 2.29 |
| 2025-12-15 | 1,927,352 | +6.0% | 581,699 | 3.31 |
| 2025-11-28 | 1,818,868 | +0.3% | 619,413 | 2.94 |
| 2025-11-14 | 1,813,497 | +23.2% | 756,102 | 2.40 |
| 2025-10-31 | 1,472,153 | -15.0% | 936,482 | 1.57 |
| 2025-10-15 | 1,731,971 | -12.1% | 716,570 | 2.42 |
| 2025-09-30 | 1,971,021 | +22.6% | 1,302,516 | 1.51 |
| 2025-09-15 | 1,607,714 | +44.0% | 1,648,934 | 1.00 |
| 2025-08-29 | 1,116,726 | +8.0% | 592,848 | 1.88 |
| 2025-08-15 | 1,034,378 | +0.8% | 694,618 | 1.49 |
| 2025-07-31 | 1,026,119 | -11.9% | 752,870 | 1.36 |
| 2025-07-15 | 1,164,456 | -4.3% | 1,580,064 | 1.00 |
| 2025-06-30 | 1,216,697 | +104.2% | 8,068,188 | 1.00 |
| 2025-06-13 | 595,786 | -94.7% | 432,013 | 1.38 |
| 2025-05-30 | 11,304,921 | +6.0% | 1,544,957 | 7.32 |
| 2025-05-15 | 10,661,396 | +19.4% | 2,190,260 | 4.87 |
| 2025-04-30 | 8,926,745 | +9.7% | 1,821,572 | 4.90 |
| 2025-04-15 | 8,136,669 | +4.7% | 3,488,782 | 2.33 |
| 2025-03-31 | 7,770,464 | +11.8% | 1,634,281 | 4.75 |
| 2025-03-14 | 6,947,547 | +4.9% | 1,439,416 | 4.83 |
| 2025-02-28 | 6,624,341 | -11.4% | 2,148,880 | 3.08 |
| 2025-02-14 | 7,477,125 | +29.9% | 4,262,987 | 1.75 |
| 2025-01-31 | 5,757,355 | +22.1% | 1,190,868 | 4.83 |
| 2025-01-15 | 4,715,570 | +8.4% | 1,823,368 | 2.59 |
| 2024-12-31 | 4,349,151 | -1.1% | 1,245,233 | 3.49 |
| 2024-12-13 | 4,396,857 | -1.0% | 2,629,955 | 1.67 |
| 2024-11-29 | 4,440,183 | -13.4% | 1,859,291 | 2.39 |
| 2024-11-15 | 5,126,494 | -1.9% | 2,197,439 | 2.33 |
| 2024-10-31 | 5,226,179 | -13.4% | 1,451,398 | 3.60 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of NKTR volume is 50.0%, up 4.5 points over the last five sessions. Over the last 30 readings it ranged from 32.6% (14 October 2026) to 73.0% (9 October 2026). The latest reading is 2.7 points below the 30-session average of 52.7%, on 261K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 130K | 261K | 50.0% | 0 |
| 2026-10-30 | 113K | 194K | 57.9% | 0 |
| 2026-10-29 | 91K | 181K | 50.7% | 0 |
| 2026-10-28 | 82K | 127K | 64.5% | 0 |
| 2026-10-27 | 76K | 148K | 51.2% | 0 |
| 2026-10-26 | 67K | 147K | 45.5% | 0 |
| 2026-10-23 | 75K | 166K | 45.1% | 0 |
| 2026-10-22 | 184K | 383K | 48.1% | 0 |
| 2026-10-21 | 125K | 205K | 60.9% | 0 |
| 2026-10-20 | 193K | 397K | 48.7% | 210 |
| 2026-10-19 | 98K | 243K | 40.2% | 0 |
| 2026-10-16 | 200K | 328K | 61.1% | 0 |
| 2026-10-15 | 184K | 335K | 54.8% | 0 |
| 2026-10-14 | 122K | 373K | 32.6% | 1,597 |
| 2026-10-13 | 195K | 400K | 48.8% | 15 |
| 2026-10-12 | 161K | 379K | 42.4% | 22 |
| 2026-10-09 | 209K | 286K | 73.0% | 0 |
| 2026-10-08 | 320K | 678K | 47.2% | 0 |
| 2026-10-07 | 301K | 599K | 50.2% | 0 |
| 2026-10-06 | 388K | 715K | 54.3% | 0 |
| 2026-10-05 | 408K | 693K | 59.0% | 0 |
| 2026-10-02 | 566K | 1.1M | 50.6% | 56,045 |
| 2026-10-01 | 1.3M | 2.7M | 48.2% | 83,067 |
| 2026-09-30 | 251K | 375K | 66.8% | 400 |
| 2026-09-29 | 195K | 292K | 66.9% | 0 |
| 2026-09-28 | 247K | 406K | 60.9% | 0 |
| 2026-09-25 | 501K | 922K | 54.3% | 21 |
| 2026-09-24 | 514K | 948K | 54.3% | 0 |
| 2026-09-23 | 345K | 721K | 47.9% | 18,107 |
| 2026-09-22 | 593K | 1.3M | 44.2% | 16,031 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in NKTR is 403 shares, up 229 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (4 August 2026) to 165,383 shares (21 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 403 | $37.92 | $15K |
| 2026-10-01 | 174 | $60.55 | $11K |
| 2026-09-30 | 423 | $59.24 | $25K |
| 2026-09-29 | 7,035 | $60.40 | $425K |
| 2026-09-22 | 147,691 | $66.84 | $9.9M |
| 2026-09-21 | 165,383 | $67.10 | $11.1M |
| 2026-09-17 | 12,437 | $67.38 | $838K |
| 2026-09-11 | 5,168 | $70.65 | $365K |
| 2026-09-10 | 7,580 | $73.32 | $556K |
| 2026-08-27 | 73 | $73.77 | $5K |
| 2026-08-25 | 8,842 | $73.69 | $652K |
| 2026-08-24 | 9,090 | $74.02 | $673K |
| 2026-08-21 | 7,074 | $74.53 | $527K |
| 2026-08-14 | 35 | $75.92 | $3K |
| 2026-08-11 | 45 | $74.86 | $3K |
| 2026-08-04 | 1 | $70.59 | $71 |
| 2026-08-03 | 91 | $70.67 | $6K |
| 2026-07-23 | 10 | $69.32 | $693 |
| 2026-07-17 | 22,864 | $67.05 | $1.5M |
| 2026-07-09 | 2 | $71.90 | $144 |
| 2026-07-07 | 1,392 | $73.15 | $102K |
| 2026-07-02 | 22,309 | $64.39 | $1.4M |
| 2026-07-01 | 76,204 | $69.81 | $5.3M |
| 2026-06-30 | 4,028 | $65.39 | $263K |
| 2026-06-26 | 50,000 | $62.03 | $3.1M |
| 2026-06-25 | 143 | $64.84 | $9K |
| 2026-06-23 | 1,895 | $65.70 | $125K |
| 2026-06-22 | 139 | $60.98 | $8K |
| 2026-06-10 | 1,899 | $56.23 | $107K |
| 2026-06-09 | 550 | $56.62 | $31K |
Insider trades
SEC Form 4, newest first. JSONInsiders at NKTR reported 2 open-market sells worth $43K in the last 90 days and no open-market buys. Latest filing: Ajer Jeffrey Robert (Director) on 2026-09-23.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | Ajer Jeffrey Robert | Director | Grant | 2K | $0.00 | $0 | 4K |
| 2026-09-23 | Brainard Diana | Director | Grant | 2K | $0.00 | $0 | 4K |
| 2026-09-23 | CHESS ROBERT | Director | Grant | 2K | $0.00 | $0 | 19K |
| 2026-09-23 | GREER R SCOTT | Director | Grant | 2K | $0.00 | $0 | 22K |
| 2026-09-23 | WHITFIELD ROY A | Director | Grant | 2K | $0.00 | $0 | 16K |
| 2026-08-18 | Zalevsky Jonathan | Chief R&D Officer | Sell | 186 | $71.98 | $13K | 10K |
| 2026-08-18 | ROBIN HOWARD W | President & CEO | Sell | 418 | $71.98 | $30K | 55K |
| 2026-06-30 | Zalevsky Jonathan | Chief R&D Officer | Sell | 6K | $70.00 | $398K | 10K |
| 2026-06-17 | ROBIN HOWARD W | President & CEO | Sell | 5K | $61.65 | $277K | 55K |
| 2026-06-17 | ROBIN HOWARD W | President & CEO | Sell | 6K | $60.81 | $334K | 60K |
| 2026-06-16 | ROBIN HOWARD W | President & CEO | Sell | 5K | $60.71 | $285K | 65K |
| 2026-06-16 | ROBIN HOWARD W | President & CEO | Sell | 5K | $59.97 | $318K | 70K |
| 2026-06-15 | Zalevsky Jonathan | Chief R&D Officer | Sell | 6K | $60.71 | $336K | 15K |
| 2026-05-19 | Zalevsky Jonathan | Chief R&D Officer | Sell | 199 | $65.51 | $13K | 21K |
| 2026-05-19 | ROBIN HOWARD W | President & CEO | Sell | 444 | $65.51 | $29K | 75K |
| 2026-02-18 | Zalevsky Jonathan | Chief R&D Officer | Sell | 180 | $73.00 | $13K | 21K |
| 2026-02-18 | ROBIN HOWARD W | President & CEO | Sell | 423 | $73.00 | $31K | 75K |
| 2026-01-20 | Zalevsky Jonathan | Chief R&D Officer | Sell | 4K | $35.67 | $138K | 21K |
| 2025-12-22 | Zalevsky Jonathan | Chief R&D Officer | Grant | 6K | $0.00 | $0 | 25K |
| 2025-12-22 | ROBIN HOWARD W | President & CEO | Grant | 22K | $0.00 | $0 | 76K |
| 2025-11-25 | Zalevsky Jonathan | Chief R&D Officer | Sell | 1K | $54.28 | $63K | 19K |
| 2025-11-25 | Wilson Mark Andrew | Chief Legal Officer | Sell | 630 | $54.28 | $34K | 22K |
| 2025-11-25 | ROBIN HOWARD W | President & CEO | Sell | 2K | $54.28 | $120K | 54K |
| 2025-11-21 | Zalevsky Jonathan | Chief R&D Officer | Grant | 3K | $0.00 | $0 | 20K |
| 2025-11-21 | Wilson Mark Andrew | Chief Legal Officer | Grant | 2K | $0.00 | $0 | 22K |
| 2025-11-21 | ROBIN HOWARD W | President & CEO | Grant | 7K | $0.00 | $0 | 56K |
| 2025-09-09 | ROBIN HOWARD W | President & CEO | Sell | 1K | $48.18 | $58K | 49K |
| 2025-09-09 | ROBIN HOWARD W | President & CEO | Sell | 2K | $47.49 | $102K | 51K |
| 2025-09-09 | ROBIN HOWARD W | President & CEO | Sell | 1K | $46.41 | $56K | 53K |
| 2025-09-09 | ROBIN HOWARD W | President & CEO | Sell | 2K | $45.16 | $95K | 54K |
| 2025-09-05 | ROBIN HOWARD W | President & CEO | Sell | 1K | $39.89 | $45K | 56K |
| 2025-09-05 | ROBIN HOWARD W | President & CEO | Sell | 2K | $38.82 | $86K | 57K |
| 2025-09-05 | ROBIN HOWARD W | President & CEO | Sell | 3K | $37.87 | $125K | 59K |
| 2025-09-04 | Zalevsky Jonathan | Chief R&D Officer | Sell | 307 | $35.69 | $11K | 17K |
| 2025-09-04 | Zalevsky Jonathan | Chief R&D Officer | Sell | 189 | $34.41 | $7K | 18K |
| 2025-09-04 | Zalevsky Jonathan | Chief R&D Officer | Sell | 432 | $33.60 | $15K | 18K |
| 2025-09-04 | Zalevsky Jonathan | Chief R&D Officer | Sell | 793 | $32.43 | $26K | 18K |
| 2025-09-04 | ROBIN HOWARD W | President & CEO | Sell | 1K | $35.80 | $41K | 63K |
| 2025-09-04 | ROBIN HOWARD W | President & CEO | Sell | 613 | $34.40 | $21K | 64K |
| 2025-09-04 | ROBIN HOWARD W | President & CEO | Sell | 1K | $33.54 | $50K | 64K |
| 2025-09-04 | ROBIN HOWARD W | President & CEO | Sell | 2K | $32.37 | $62K | 66K |
| 2025-09-02 | Zalevsky Jonathan | Chief R&D Officer | Sell | 485 | $30.10 | $15K | 19K |
| 2025-09-02 | ROBIN HOWARD W | President & CEO | Sell | 2K | $30.16 | $45K | 68K |
| 2025-08-19 | Zalevsky Jonathan | Chief R&D Officer | Sell | 725 | $26.59 | $19K | 20K |
| 2025-08-19 | Wilson Mark Andrew | Chief Legal Officer | Sell | 676 | $26.59 | $18K | 20K |
| 2025-08-19 | ROBIN HOWARD W | President & CEO | Sell | 2K | $26.59 | $42K | 69K |
| 2025-05-19 | ROBIN HOWARD W | President & CEO | Sell | 23K | $0.67 | $16K | 1.1M |
| 2025-05-19 | Wilson Mark Andrew | Chief Legal Officer | Sell | 10K | $0.67 | $7K | 314K |
| 2025-05-19 | Zalevsky Jonathan | Chief R&D Officer | Sell | 11K | $0.67 | $7K | 306K |
| 2025-02-19 | ROBIN HOWARD W | President & CEO | Sell | 24K | $1.01 | $24K | 1.1M |
| 2025-02-19 | Wilson Mark Andrew | Chief Legal Officer | Sell | 11K | $1.01 | $11K | 324K |
| 2025-02-19 | Zalevsky Jonathan | Chief R&D Officer | Sell | 10K | $1.01 | $10K | 317K |
| 2024-12-24 | Wilson Mark Andrew | Chief Legal Officer | Sell | 17K | $0.89 | $15K | 335K |
| 2024-12-23 | Wilson Mark Andrew | Chief Legal Officer | Sell | 33K | $0.90 | $30K | 352K |
| 2024-12-19 | Zalevsky Jonathan | Chief R&D Officer | Sell | 51K | $0.94 | $48K | 327K |
| 2024-12-18 | ROBIN HOWARD W | President & CEO | Sell | 85K | $0.99 | $84K | 1.1M |
| 2024-12-17 | ROBIN HOWARD W | President & CEO | Sell | 47K | $1.01 | $47K | 1.2M |
| 2024-12-13 | ROBIN HOWARD W | President & CEO | Grant | 411K | $0.00 | $0 | 1.2M |
| 2024-12-13 | Wilson Mark Andrew | Chief Legal Officer | Grant | 166K | $0.00 | $0 | 385K |
| 2024-12-13 | Zalevsky Jonathan | Chief R&D Officer | Grant | 135K | $0.00 | $0 | 378K |
| 2024-11-19 | ROBIN HOWARD W | President & CEO | Sell | 16K | $1.01 | $16K | 832K |
| 2024-11-19 | Wilson Mark Andrew | Chief Legal Officer | Sell | 6K | $1.01 | $6K | 219K |
| 2024-11-19 | Zalevsky Jonathan | Chief R&D Officer | Sell | 8K | $1.01 | $8K | 243K |
| 2024-08-19 | ROBIN HOWARD W | President & CEO | Sell | 15K | $1.28 | $19K | 848K |
| 2024-08-19 | Wilson Mark Andrew | Chief Legal Officer | Sell | 6K | $1.28 | $7K | 225K |
| 2024-08-19 | Zalevsky Jonathan | Chief R&D Officer | Sell | 7K | $1.28 | $9K | 251K |
| 2024-06-14 | CHESS ROBERT | Director | Sell | 20K | $1.20 | $23K | 255K |
| 2024-05-17 | Wilson Mark Andrew | Chief Legal Officer | Sell | 6K | $1.75 | $11K | 230K |
| 2024-05-17 | Zalevsky Jonathan | Chief R&D Officer | Sell | 7K | $1.75 | $13K | 258K |
| 2024-05-17 | ROBIN HOWARD W | President & CEO | Sell | 17K | $1.75 | $29K | 863K |
| 2024-05-10 | KROIN DAVID | TenPercentOwner | Sell | 56K | $1.78 | $100K | 18.3M |
| 2024-02-20 | ROBIN HOWARD W | President & CEO | Sell | 20K | $0.68 | $14K | 880K |
| 2024-02-20 | Wilson Mark Andrew | Chief Legal Officer | Sell | 8K | $0.68 | $5K | 237K |
| 2024-02-20 | Zalevsky Jonathan | Chief R&D Officer | Sell | 9K | $0.68 | $6K | 265K |
| 2023-11-17 | ROBIN HOWARD W | President & CEO | Sell | 20K | $0.49 | $10K | 900K |
| 2023-11-17 | Wilson Mark Andrew | Chief Legal Officer | Sell | 7K | $0.49 | $4K | 244K |
| 2023-11-17 | Zalevsky Jonathan | Chief R&D Officer | Sell | 10K | $0.49 | $5K | 274K |
| 2023-09-18 | Ajer Jeffrey Robert | Director | Sell | 4K | $0.69 | $3K | 34K |
| 2023-09-18 | Curet Myriam | Director | Sell | 4K | $0.69 | $3K | 27K |
| 2023-08-16 | ROBIN HOWARD W | President & CEO | Sell | 20K | $0.78 | $16K | 920K |
| 2023-08-16 | Wilson Mark Andrew | Chief Legal Officer | Sell | 7K | $0.78 | $6K | 251K |
| 2023-08-16 | Zalevsky Jonathan | Chief R&D Officer | Sell | 10K | $0.78 | $8K | 284K |
| 2023-06-14 | WHITFIELD ROY A | Director | Sell | 30K | $0.57 | $17K | 216K |
| 2023-05-16 | ROBIN HOWARD W | President & CEO | Sell | 20K | $0.72 | $15K | 940K |
| 2023-05-16 | Wilson Mark Andrew | Chief Legal Officer | Sell | 8K | $0.72 | $5K | 258K |
| 2023-05-16 | Zalevsky Jonathan | Chief R&D Officer | Sell | 10K | $0.72 | $7K | 293K |
| 2023-02-16 | ROBIN HOWARD W | President & CEO | Sell | 20K | $3.00 | $59K | 960K |
| 2023-02-16 | Thomsen Jillian B. | Chief Financial Officer | Sell | 10K | $3.00 | $31K | 313K |
| 2023-02-16 | Wilson Mark Andrew | Chief Legal Officer | Sell | 8K | $3.00 | $25K | 265K |
| 2023-02-16 | Zalevsky Jonathan | Chief R&D Officer | Sell | 10K | $3.00 | $31K | 303K |
| 2022-11-16 | ROBIN HOWARD W | President & CEO | Sell | 38K | $3.57 | $136K | 980K |
| 2022-11-16 | Thomsen Jillian B. | Chief Financial Officer | Sell | 11K | $3.57 | $40K | 324K |
| 2022-11-16 | Wilson Mark Andrew | Chief Legal Officer | Sell | 9K | $3.57 | $31K | 272K |
| 2022-11-16 | Zalevsky Jonathan | Chief R&D Officer | Sell | 13K | $3.57 | $48K | 314K |
| 2022-09-23 | Ajer Jeffrey Robert | Director | Sell | 4K | $3.16 | $13K | 39K |
| 2022-09-23 | Curet Myriam | Director | Sell | 4K | $3.16 | $13K | 32K |
| 2022-09-22 | CHESS ROBERT | Director | Sell | 10K | $0.67 | $7K | 275K |
| 2022-09-22 | CHESS ROBERT | Director | Sell | 5K | $3.19 | $16K | 228K |
| 2022-09-16 | Ajer Jeffrey Robert | Director | Grant | 10K | $0.00 | $0 | 43K |
| 2022-09-16 | Brainard Diana | Director | Grant | 10K | $0.00 | $0 | 29K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON15 Form 144 notices on file for NKTR worth $8.1M at the prices reported; 2 in the last 90 days worth $43K. Latest: Zalevsky Jonathan filed on 2026-08-18 to sell 186 shares ($13K) from 2026-08-18.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-18 | Zalevsky JonathanOfficer | 186 | $13K | 0.001% | 2026-08-18 | Fidelity Brokerage Services LLC |
| 2026-08-18 | ROBIN HOWARD WOfficer, Director | 418 | $30K | 0.001% | 2026-08-18 | Fidelity Brokerage Services LLC |
| 2026-06-30 | JONATHAN ZALEVSKYOfficer | 6K | $371K | 0.017% | 2026-06-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-17 | ROBIN HOWARD WOfficer, Director | 10K | $603K | 0.030% | 2026-06-17 | Fidelity Brokerage Services LLC |
| 2026-06-16 | ROBIN HOWARD WOfficer, Director | 10K | $610K | 0.030% | 2026-06-16 | Fidelity Brokerage Services LLC |
| 2026-06-15 | JONATHAN ZALEVSKYOfficer | 6K | $329K | 0.016% | 2026-06-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-19 | Zalevsky JonathanOfficer | 199 | $13K | 0.001% | 2026-05-19 | Fidelity Brokerage Services LLC |
| 2026-05-19 | ROBIN HOWARD WOfficer, Director | 444 | $29K | 0.001% | 2026-05-19 | Fidelity Brokerage Services LLC |
| 2026-03-13 | Wilson Mark AndrewFormer Officer | 79K | $5.7M | 0.274% | 2026-03-13 | Fidelity Brokerage Services LLC |
| 2026-02-18 | ROBIN HOWARD WOfficer, Director | 423 | $31K | 0.002% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Zalevsky JonathanOfficer | 180 | $13K | 0.001% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-01-20 | Zalevsky JonathanOfficer | 4K | $138K | 0.019% | 2026-01-20 | Fidelity Brokerage Services LLC |
| 2025-11-25 | ROBIN HOWARD WOfficer, Director | 2K | $130K | 0.011% | 2025-11-25 | Fidelity Brokerage Services LLC |
| 2025-11-25 | Wilson Mark AndrewOfficer | 630 | $37K | 0.003% | 2025-11-25 | Fidelity Brokerage Services LLC |
| 2025-11-25 | Zalevsky JonathanOfficer | 1K | $68K | 0.006% | 2025-11-25 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON11 holders report 5% or more of NKTR in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 15.0% of the class (4,303,188 shares), filed 2026-05-06 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-28 | 13G/Ano. 2 | Sina Toussiindividual, parent holding company | 3.3M | 9.8% | 2026-09-25 |
| 2026-09-28 | 13G/Ano. 2 | Two Seas Capital GP LLCother entity, parent holding company | 3.3M | 9.8% | 2026-09-25 |
| 2026-09-28 | 13G/Ano. 2 | Two Seas Capital LPinvestment adviser, partnership | 3.3M | 9.8% | 2026-09-25 |
| 2026-08-14 | 13G/Ano. 2 | LAMPERT MARK Nindividual | 2.4M | 7.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | BVF PARTNERS L P/ILinvestment adviser, partnership | 2.4M | 7.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | BVF INC/ILcorporation | 2.4M | 7.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | BVF GP HOLDINGS LLCother entity | 2.2M | 6.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | BVF I GP LLCother entity | 1.3M | 3.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 1.3M | 3.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | BIOTECHNOLOGY VALUE FUND II LPpartnership | 946K | 2.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | BVF II GP LLCother entity | 946K | 2.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Biotechnology Value Trading Fund OS LPpartnership | 157K | 0.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | BVF Partners OS Ltd.corporation | 157K | 0.5% | 2026-06-30 |
| 2026-07-31 | 13G | Vanguard Capital Managementinvestment adviser | 1.7M | 5.2% | 2026-06-30 |
| 2026-07-29 | 13G | BlackRock, Inc.parent holding company | 2.6M | 7.8% | 2026-06-30 |
| 2026-05-06 | 13G/Ano. 1 | FMR LLCparent holding company | 4.3M | 15.0% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 4.3M | 15.0% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 1 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-13 | 13G/Ano. 1 | G1 Execution Services, LLCbroker-dealer, other entity | 810K | 4.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 1 | Susquehanna Portfolio Strategies, LLCother entity | 810K | 4.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 1 | Susquehanna Securities, LLCbroker-dealer, other entity | 810K | 4.0% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 2 | TCG Crossover GP II, LLCother entity | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | TCG Crossover Fund II, L.P.partnership | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Chen Yuindividual | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Nantahala Capital Management, LLCinvestment adviser | 419K | 2.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Wilmot B. Harkeyparent holding company | 419K | 2.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Daniel Mackparent holding company | 419K | 2.2% | 2025-09-30 |
| 2025-10-28 | 13G/Ano. 1 | Israel A. Englanderindividual | 571K | 3.0% | 2025-09-30 |
| 2025-10-28 | 13G/Ano. 1 | Millennium Management LLCother entity | 571K | 3.0% | 2025-09-30 |
| 2025-10-28 | 13G/Ano. 1 | Millennium Group Management LLCother entity | 571K | 3.0% | 2025-09-30 |
| 2025-10-28 | 13G/Ano. 1 | Integrated Core Strategies (US) LLCother entity | 334K | 1.8% | 2025-09-30 |
13F holders
Tracked managers holding NKTR at their latest 13F. JSON4 of the 30 tracked managers held NKTR at their latest 13F, $130.0M in total at quarter-end prices. Two Sigma Investments is the largest at $83.9M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 1.2M | $83.9M | 0.06% | +271K |
| Millennium Management | 2026-06-30 | 478K | $33.4M | 0.01% | +74K |
| Citadel Advisors | 2026-06-30 | 160K | $11.2M | 0.00% | -354K |
| AQR Capital Management | 2026-06-30 | 23K | $1.6M | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Nektar Therapeutics reported revenue of $10.1M, down 9.3% from the same quarter a year earlier, and net loss of $40.6M (-1.23 diluted EPS). In FY 2025 it generated -$208.5M of operating cash flow.
- Cash
- $39.3M
- Equity
- $903.1M
- Total assets
- $1.10B
- Shares outstanding
- 34,142,994
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $10.1M | -$40.6M | -401.0% | -1.23 |
| Q1 FY 2026 | 2026-03-31 | $10.9M | -$44.9M | -413.4% | -1.82 |
| Q4 FY 2025derived | 2025-12-31 | $21.8M | -$36.1M | -165.4% | n/a |
| Q3 FY 2025 | 2025-09-30 | $11.8M | -$35.5M | -301.3% | -1.87 |
| Q2 FY 2025 | 2025-06-30 | $11.2M | -$41.6M | -372.2% | -2.95 |
| Q1 FY 2025 | 2025-03-31 | $10.5M | -$50.9M | -486.4% | -3.62 |
| Q4 FY 2024derived | 2024-12-31 | $29.2M | $7.3M | 24.9% | n/a |
| Q3 FY 2024 | 2024-09-30 | $24.1M | -$37.1M | -153.6% | -2.66 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $55.2M | -$164.1M | -$208.5M | $171K | $0 | n/a |
| FY 2024 | 2024-12-31 | $98.4M | -$119.0M | -$175.7M | $1.5M | $3.0M | n/a |
| FY 2023 | 2023-12-31 | $90.1M | -$276.1M | -$192.6M | $865K | $0 | n/a |
| FY 2022 | 2022-12-31 | $92.1M | -$368.2M | -$304.0M | $5.7M | n/a | n/a |
| FY 2021 | 2021-12-31 | $101.9M | -$523.8M | -$412.7M | $15.0M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-07 from the cover page.
What this page is
Nektar Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Nektar Therapeutics (NKTR), SEC CIK 906709, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-18.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-28.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-13.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-23.JSON and CSV
- Company record
- EDGAR filing index for CIK 906709Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of NKTR is sold short?
6,997,725 shares were held short at the 2026-10-15 settlement, 3.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is NKTR's daily short volume?
On 2026-11-02, 130,254 of the 260,674 NKTR shares reported to FINRA were sold short, 50.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does NKTR have fails to deliver?
The SEC's latest file shows 403 NKTR shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are NKTR insiders buying or selling?
Insiders at NKTR reported 2 open-market sells worth $43K in the last 90 days and no open-market buys. Latest filing: Ajer Jeffrey Robert (Director) on 2026-09-23.
Have NKTR insiders filed to sell?
15 Form 144 notices on file for NKTR worth $8.1M at the prices reported; 2 in the last 90 days worth $43K. Latest: Zalevsky Jonathan filed on 2026-08-18 to sell 186 shares ($13K) from 2026-08-18.
Who owns 5% or more of NKTR?
11 holders report 5% or more of NKTR in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 15.0% of the class (4,303,188 shares), filed 2026-05-06 for an event on 2026-03-31.
What did NKTR report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Nektar Therapeutics reported revenue of $10.1M, down 9.3% from the same quarter a year earlier, and net loss of $40.6M (-1.23 diluted EPS). In FY 2025 it generated -$208.5M of operating cash flow.
Which tracked 13F managers own NKTR?
4 of the 30 tracked 13F managers held NKTR shares at their latest filing, $130.0M in all. The largest: Two Sigma Investments (1.2M shares, $83.9M), Izzy Englander's Millennium Management (478K shares, $33.4M), Ken Griffin's Citadel Advisors (160K shares, $11.2M), Cliff Asness's AQR Capital Management (23K shares, $1.6M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.